Phase 3 N=51 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Eosinophilic Esophagitis · Gastroesophageal Reflux Disease · EE
Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=305 Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
Non Erosive Reflux Disease · Chronic Gastritis
Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants
Phase 3 N=26 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…
N/A N=1,995 Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
Gastroesophageal Reflux Disease
Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale
Phase 3 N=288 A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: Percentage of Participants With Complete Relief of Heartburn at Final Evaluation — 20.9; 34.4; 43.6 Percentage of participants
N/A N=1,045 Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
Sleep Disorders · Non-Erosive Reflux Disease · Gastroesophageal Reflux Disease
Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale
Phase 2 N=458 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Non-Erosive Gastro-Esophageal Reflux Disease · Heartburn
Primary: Percentage of Evaluable Heartburn Episodes Completely Relieved Within 3 Hours and With No Further Heartburn Reported for 24 Hours After Taking Study Drug — 56.0; 60.6…
Phase 4 N=276 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
Gastroesophageal Reflux Disease
Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants
Phase 3 N=484 Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
Non-erosive Gastroesophageal Reflux Disease
Primary: Percentage of Days Without Symptoms of Heartburn — 61.50; 72.55 percentage of days — p=0.0643
N/A N=43 Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
Gastroesophageal Reflux · Laryngopharyngeal Reflux
Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale
Phase 4 N=337 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Gastroesophageal Reflux Disease
Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms
Phase 4 N=3,029 Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
GERD
Primary: Efficacy of Three Strategies of Long-term Treatment — 10.6; 7.8; 43 Percentage of participants with failure
Phase 3 N=564 Reflux Esophagitis Phase III Study (Maintenance Treatment)
Reflux Esophagitis
Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants
N/A N=8,616 Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)
Erosive Gastroesophageal Reflux Disease · Non-Erosive Reflux Disease
Primary: Assessment of the Severity of Sleep Disturbances — 13.8; 77.4; 38.2; 20.0 percentage of participants
Phase 3 N=554 Esomeprazole (NEXIUM) vs. Surgery
Gastroesophageal Reflux
Primary: Number of Participants With Treatment Failure at 5 Years — 33; 19 participants
N/A N=374 The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department
Gastroesophageal Reflux
Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
N/A N=76 Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial
Gastroesophageal Reflux Disease
Primary: CLINICAL OUTCOME OF FEEDING SUCCESS — 33; 44 percentage of participants — p=0.28
Phase 3 N=572 Reflux Esophagitis Phase III Study (Initial Treatment)
Reflux Esophagitis
Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…
N/A N=95 Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device
Laryngopharyngeal Reflux
Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05
Phase 3 N=366 A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors
GERD
Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…
N/A N=65 Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease
Primary: Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention — -1.2397; 0.0869 scores on a scale — p=0.0002
Phase 2 N=27 TLESR-impedance Study in Patients
Reflux Episodes
Primary: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs) 0-3 Hours Post Meal, Post Third Dose — 11.6; 15.5 Relaxations
N/A N=44 An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter
Gastroesophageal Reflux Disease
Primary: To Evaluate the Incidence of All Adverse Events at Various Time Points. — 29 participants
Phase 3 N=776 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Non-Erosive Gastro-Esophageal Reflux Disease · Heartburn
Primary: Percentage of Days Without Daytime or Nighttime Heartburn — 27.7; 44.8; 44.4 Percentage of days — p=<0.0001
N/A N=24 Correlates of GERD Symptom Severity
GERD
Primary: Association of Change in Patient's GSR From Beginning to End of Study Visit With GERD Symptom Severity 2 Weeks Later — -0.94; -1.70 micro-Siemens — p=0.034
N/A N=68 Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD
Gastroesophageal Reflux Disease (GERD)
Primary: The Number of Reflux in GERD Patients — 33.6; 42.8; 81.0; 53.1 episodes — p=0.002
Phase 4 N=35 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD
Gastroesophageal Reflux Disease
Primary: Number of Gastroesophageal Refluxes — 42.4 refluxes — p=0.000002
N/A N=75 Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
Gastro-esophageal Reflux Disease
Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change
Phase 3 N=80 Gastroesophageal Reflux Treatment in Scleroderma
Gastroesophageal Reflux Disease · Systemic Sclerosis · Scleroderma
Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)